Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 349Neoplasms 315Carcinoma, Non-Small-Cell Lung 277Prostatic Neoplasms 221Colorectal Neoplasms 208Lung Neoplasms 177Multiple Myeloma 149Ovarian Neoplasms 136Pancreatic Neoplasms 130Neoplasm Metastasis 123Leukemia, Myeloid, Acute 121Melanoma 104Squamous Cell Carcinoma of Head and Neck 90Recurrence 84Lymphoma 84Carcinoma, Renal Cell 84Lymphoma, Non-Hodgkin 82Endometrial Neoplasms 82Stomach Neoplasms 80Brain Neoplasms 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Carcinoma, Hepatocellular 77Head and Neck Neoplasms 71Glioma 70Glioblastoma 70Uterine Cervical Neoplasms 67Urinary Bladder Neoplasms 65Leukemia, Lymphocytic, Chronic, B-Cell 65Sarcoma 63Hematologic Neoplasms 62

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hamartoma Syndrome, Multiple × 30 days × Clear all
NCT07218575 2026-06-04

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Boston Children's Hospital

Phase 2/3 Not yet recruiting
60 enrolled

Autistic Disorder, Hamartoma Syndrome, Multiple

NCT00040222 2026-06-01

Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

National Institutes of Health Clinical Center (CC)

Completed
377 enrolled
BreastGynecologic

Breast Cancer, Familial, Breast Neoplasms, Hamartoma Syndrome, Multiple, Ovarian Neoplasms, Peutz-Jeghers Syndrome, Li-Fraumeni Syndrome, Risk Reduction Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡